The dysregulated activity of effector cells of the T H 1 and T H 17 subsets of helper T cells results in the development of tissue inflammation and autoimmunity. Myelin-specific T H 1 and T H 17 cells, for example, contribute to disease pathogenesis in multiple sclerosis (MS) 1 and its animal model, experimental autoimmune encephalomyelitis (EAE) 2 . During EAE, dendritic cells (DCs) control the activation and differentiation of myelin-specific effector T cells and regulatory T cells (T reg cells) 3, 4 . Moreover, DCs isolated from patients with MS produce large amounts of T H 1-and T H 17-polarizing cytokines 5 , which suggests that DCs promote the generation of the pathogenic T cell response in MS. Indeed, DCs control several pathogenic mechanisms associated with the development of central nervous system (CNS) autoimmunity. DCs promote the entry of T cells into the CNS 6 , the activation and differentiation of pathogenic T cells in the CNS 3 and the spreading of the autoimmune response to new CNS epitopes 7 . Thus, it is important to study the pathways that regulate DC activity during the course of autoimmunity, to identify mechanisms of disease pathogenesis and also to develop new approaches for therapeutic intervention.
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IL-27 is a cytokine structurally related to IL-12 and is composed of a p28 subunit and the product of Epstein-Barr virus-induced gene 3 (Ebi3) 8 . IL-27 signals through a receptor composed of the common IL-6 receptor chain gp130 (which is used by several other members of the IL-6 and IL-12 families) and a unique IL-27 receptor α-chain (IL-27RA) that is homologous to the IL-12Rβ2 chain of the IL-12 receptor 8 . IL-27 is produced by DCs in response to activation via Toll-like receptors through a mechanism that involves the autocrine effects of interferon-β (IFN-β) 9 . Indeed, the therapeutic effects of IFN-β administration on relapsing-remitting MS have been linked to the induction of IL-27 production by DCs 10 .
On the basis of its structural homology to IL-12 and its ability to trigger IFN-γ production, IL-27 was initially thought to be a proinflammatory cytokine 11 . However, it was subsequently discovered that IL-27 suppresses T H 1, T H 2 and T H 17 responses and limits CNS inflammation in several experimental models 8 . In the EAE model, the administration of IL-27 inhibits disease development 12 . Conversely, the lack of a functional IL-27 receptor results in exacerbated T H 17 responses and the worsening of EAE 12, 13 . IL-27 acts directly on T cells to inhibit the development of pathogenic T H 17 cells and to promote the differentiation of IL-10-producing type 1 T reg cells (Tr1 cells) [12] [13] [14] [15] [16] [17] . Thus, the arrest of EAE by IL-27 is thought to reflect its direct effects on T cells. However, several cell types beyond T cells express the IL-27 receptor, but the relevance of IL-27 signaling in those cells for the control of EAE and autoimmunity is unknown.
DCs express a functional IL-27 receptor 18 ; however, although IL-27 has been reported to interfere with the activation of DCs in vitro [18] [19] [20] , the physiological relevance of IL-27 signaling in DCs and its effects on the control of the T cell response and autoimmunity are unknown. In this work, we studied the effects of IL-27 signaling in DCs on the differentiation of effector T cells and T reg cells and CNS autoimmunity. We found that IL-27 signaling in DCs upregulated expression of the immunoregulatory molecule CD39 (encoded by Entpd1) and limited the development of EAE. CD39 expressed by conventional DCs (cDCs) reduced the extracellular concentration of ATP and decreased ATP-triggered activation of the NLRP3 inflammasome. Moreover, we RESULTS Higher IL-27RA expression in cDCs than in plasmacytoid DCs To investigate the role of IL-27 signaling in DCs on the regulation of autoimmunity, we first analyzed the expression of IL-27RA in plasmacytoid DCs (pDCs; F4/80 − CD11b − CD11c lo B220 + MHC class II lo Ly6c + ) and cDCs (F4/80 − CD11b + CD11c + B220 − MHC class II + Ly6c − ) isolated from naive mice by flow cytometry ( Supplementary  Fig. 1 ). IL-27RA was expressed mainly in cDCs, with only low or absent expression on pDCs (Fig. 1a) . We obtained similar results for IL-27RA expression by quantitative PCR and immunoblot analysis of sorted pDCs and cDCs (Fig. 1b,c) . Thus, the expression pattern of IL-27RA suggested that IL-27 controls the activity of cDCs.
IL-27 modulates the function of cDCs
After antigen uptake in the presence of DC-maturing stimuli, DCs upregulate their expression of major histocompatibility complex (MHC) class II and costimulatory molecules 21 . To investigate the effects of IL-27 on DC activation, we pretreated splenic cDCs from naive mice with vehicle or IL-27 and studied their response to activation with lipopolysaccharide from Escherichia coli (ecLPS). Pretreatment of cDCs with IL-27 followed by activation with ecLPS led to significantly lower expression of MHC class II and the costimulatory molecules CD40, CD80 and CD86 than that of cDCs activated with ecLPS without IL-27 pretreatment ( Fig. 2a and Supplementary Fig. 2) .
DCs control T cell differentiation via the secretion of polarizing cytokines 21 . Pretreatment of splenic cDCs with IL-27 followed by activation with ecLPS led to significantly lower production of IL-12 and of IL-6 and IL-23 (which promote the differentiation of T H 1 and T H 17 cells, respectively) than that of cDCs activated with ecLPS without IL-27 pretreatment (Fig. 2b) . Pretreatment of cDCs with IL-27 followed by activation with ecLPS also upregulated Il27 expression (Fig. 2c) , which suggested a positive feedback loop for IL-27 production. Indeed, in those conditions we detected increased production of IFN-β (Fig. 2b) , which is reported to act in an autocrine manner to trigger IL-27 production 9 . We also detected increased production of IL-10 in those conditions and increased production of and transforming growth factor-β1 (TGF-β1) only in response to treatment with IL-27 (Fig. 2b) . Together these data suggested that IL-27 decreased the production of cytokines that promote the differentiation of effector T H 1 and T H 17 cells, while it enhanced the production of antiinflammatory cytokines by cDCs.
The effects of IL-27 on the expression of MHC class II, costimulatory molecules and cytokines suggested that IL-27 affects the ability of DCs to activate and polarize T cells into specific subsets. Thus, we pretreated cDCs with IL-27 and activated them with ecLPS, then extensively washed them and assessed their ability to activate naive 2D2 CD4 + T cells in the presence of their cognate target antigen: an epitope of amino acids 35-55 of myelin oligodendrocyte glycoprotein (MOG ). Pretreatment of cDCs with IL-27 followed by activation with ecLPS led to a significantly lower proliferative response of naive 2D2 T cells to MOG than that elicited by cDCs treated with ecLPS without IL-27 pretreatment (Fig. 2d) . Moreover, the cDCs pretreated with IL-27 and activated with ecLPS had a decreased ability to induce the production of IFN-γ and IL-17 by T cells, as measured by enzyme-linked immunosorbent assay and intracellular cytokine staining (Fig. 2e,f) . Conversely, pretreatment of cDCs with IL-27 before activation with ecLPS boosted their ability to promote the differentiation of IL-10 + and Foxp3 + CD4 + T cells (Fig. 2e,f) . We observed similar effects for bone marrow-derived DCs pretreated with IL-27 and activated with ecLPS (data not shown).
IL-27 is known to act directly on T cells to suppress their differentiation into effector T cells 12, [15] [16] [17] . We found that cDCs pretreated IL-27 and activated with ecLPS showed a diminished ability to trigger the production of IFN-γ and IL-17 by T cells in the presence of exogenously added T H 1-and T H 17-polarizing cytokines than that of cDCs activated with ecLPS without IL-27 pretreatment (Fig. 2g) . Conversely, pretreatment of cDCs with IL-27 increased IL-10 production and expression of the transcription factor Foxp3 in T cells when we added Tr1-polarizing cytokines or cytokines that polarize differentiation into Foxp3 + T reg cells to the coculture (Fig. 2g,h) , which suggested that IL-27 signaling in DCs modulated T cell differentiation in vivo even in the context of inflammation or other physiological conditions that generate a polarizing cytokine milieu. Together these data demonstrated that IL-27 signaling controlled the antigenpresenting function of cDCs.
IL-27RA in DCs limits EAE development IL-27 has an important role in the control of CNS inflammation during EAE 12, 13, 15 . In agreement with published reports 13 , we found a significant worsening of EAE in IL-27RA-deficient (Il27ra −/− ) mice, characterized by an increase in the frequency of CNS-infiltrating IFN-γ + and IL-17 + CD4 + T cells and a lower frequency of IL-10 + CD4 + T cells (Supplementary Fig. 3a,b) . Il27ra −/− mice also showed an increased recall response to MOG and an increased frequency of CD4 + CD44 + CD40L hi IFNγ + , IL-17 + and IFN-γ + IL-17 + CD4 + T cells in the lymph nodes and spleen, concomitant with a decreased frequency of Foxp3 + and IL-10 + CD4 + T cells ( Supplementary  Fig. 3c,d) .
The published effects of IL-27 on encephalitogenic and T reg cells 14, 15, 17 would suggest that the worsening of EAE in the Il27ra −/− mice resulted from the lack of IL-27 signaling in T cells. However, the Il27ra −/− mice had non-cell-specific deletion of IL-27RA; thus, it remained possible that IL-27 acted on additional cells beyond T cells to limit the development of EAE. To investigate the role of IL-27 signaling in DCs during EAE, we isolated cDCs from wild-type and Il27ra −/− mice 21 d after disease induction. We found that cDCs from Il27ra −/− mice showed an increased ability to activate naive 2D2 T cells in the presence of MOG (Supplementary Fig. 3e ), In vivo, DCs are influenced by their interactions with T cells and the cytokine milieu. Thus, the increased antigen-presenting function of cDCs isolated from Il27ra −/− mice might have reflected the exposure of the DCs to a more inflammatory cytokine milieu and not direct effects of IL-27 on DCs. To study the role of IL-27 signaling in DCs during EAE, we used a chimera-based approach to generate mice lacking IL-27RA expression in DCs ( Supplementary  Fig. 4a ). For this, we reconstituted lethally irradiated wild-type mice with bone marrow cells from mice that express the diphtheria toxin receptor (DTR) under the control of the promoter of the gene encoding CD11c (Itgax; called 'CD11c-DTR' mice here). After reconstitution, these mice can be depleted of CD11c + DCs by the administration of diphtheria toxin (DTx) 22 . DTx cannot be chronically administered to CD11c-DTR mice because of adverse side effects; however, no adverse effects are associated with the chronic administration of DTx to chimeras generated by the reconstitution of wild-type mice with bone marrow from CD11c-DTR mice (CD11c-DTR→WT) 4 . Thus, 2 months after reconstitution of wild-type mice with CD11c-DTR bone marrow, we depleted those CD11c-DTR→ WT chimeras of DTR + DCs by chronic administration of DTx and reconstituted their DC compartment with DC precursors from wildtype mice (to generate 'DC(WT)' mice) or from Il27ra −/− mice (to generate 'DC(IL-27RA-KO)' mice) (Supplementary Fig. 4b ). We administered DTx to DC(WT) and DC(IL-27RA-KO) mice once every other day until the completion of the experiment and detected no antibodies to DTx after 2 months of DTx administration (Supplementary Fig. 4c) .
DC(IL-27RA-KO) mice had significantly lower IL-27RA expression in cDCs but not in other antigen-presenting cell (APC) populations than did DC (WT) mice ( Fig. 3a and Supplementary Fig. 4d ).
We detected no difference between DC(WT) and DC(IL-27RA-KO) mice in the frequency or absolute number of DCs ( Supplementary  Fig. 4e ). Treatment with MOG(35-55) resulted in faster development of EAE in DC(IL-27RA-KO) mice than in DC(WT) mice; DC(IL-27RA-KO) mice also reached significantly higher disease scores than did their DC(WT) counterparts (Fig. 3b) . The worsening of EAE in DC(IL-27RA-KO) mice was associated with a greater frequency of T H 1 and T H 17 cells in the CNS and significantly fewer IL-10 + T cells than that in DC(WT) mice (Fig. 3c) . Moreover, analysis of the CD4 + CD44 + CD40L hi splenic T cell compartment revealed a higher recall proliferative response to MOG(35-55) and a higher frequency of IFN-γ + and IL-17 + CD4 + cells in DC(IL-27RA-KO) mice than in DC(WT) mice, concomitant with a lower frequency of Foxp3 + T reg cells and IL-10 + CD4 + cells in DC(IL-27RA-KO) mice than in DC(WT) mice (Fig. 3d,e) . We obtained similar results when we induced EAE by transferring MOG(35-55)-reactive T H 1 or T H 17 cells (Supplementary Fig. 4f-h) .
To study the effects of IL-27 signaling in DCs during EAE, we isolated cDCs from DC(WT) and DC(IL-27RA-KO) mice 21 d after EAE induction. cDCs from DC(IL-27RA-KO) mice had higher expression of the proinflammatory cytokines IL-6, IL-12 and IL-23, concomitant with lower expression of IL-10 and IL-27, than that of DC(WT) mice (Fig. 3f) . We confirmed those results by additional quantitative profiling analyses, which detected a pronounced proinflammatory transcription profile in cDCs isolated from DC(IL-27RA-KO) mice during EAE (Fig. 3g) . Moreover, cDCs from DC(IL-27RA-KO) mice showed an greater ability to activate the proliferation of 2D2 CD4 + T cell and promoted the production of increased amounts of IFN-γ and IL-17 and decreased quantities of IL-10 and TGF-β1 than did their DC(WT) counterparts (Fig. 3h,i ). Together these data showed that IL-27 acted on cDCs in vivo to limit the development of encephalitogenic T cells and EAE. 
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Transcriptional effects of IL-27 on DCs
To investigate the mechanisms that mediate the effects of IL-27 on DCs, we analyzed by microarray the expression profiles of primary splenic cDCs isolated from naive wild-type mice and treated in vitro with IL-27. Study of the expression data by Ingenuity pathway analysis identified significantly lower expression of genes encoding proinflammatory molecules associated with the NF-κB and Tolllike receptor signaling pathways in IL-27-treated cDCs than in untreated cDCs (P = 2.16 × 10 −21 and P = 4.55 × 10 −27 , respectively; Supplementary Fig. 5a,b) . Conversely, treatment with IL-27 led to a significant increase over time in the expression of Tnip3 and Tnfaip3, which encode molecules known to inhibit NF-κB activation 23 (Supplementary Fig. 5c ). We also found significant upregulation over time of Ido1, Ido2, Il27, Il10 and Entpd1, which encode anti-inflammatory molecules (Supplementary Fig. 5c ).
We used the NetGenerator algorithm to analyze the transcriptional response of DCs to IL-27. This algorithm integrates expression profiles in a model with prior 'knowledge' of the genes under investigation and their connections 24 . The resulting model suggested that IL-27 controlled the expression of the anti-inflammatory molecules described above in a manner dependent on the transcription factors STAT1 and STAT3 (Supplementary Fig. 5d ). Together these data showed that IL-27 limited the inflammatory response of cDCs and triggered the expression of tolerogenic molecules.
CD39 mediates the inhibitory effects of IL-27 on DCs
Our transcriptional profiling studies identified several candidate molecules that probably mediate the effects of IL-27 signaling in cDCs on the activation of T cells. To identify the mechanisms that mediate the effects of IL-27 on the antigen-presenting function of cDCs, we used blocking antibodies to IL-27, IL-10, IFN-β or TGF-β, or the indoleamine 2,3-deoxygenase (IDO)-specific inhibitor 1-methyl-dtryptophan (1-D-MT). We pretreated splenic cDCs with IL-27 and then treated them with ecLPS, extensively washed the cells and used them to activate naive CD4 + T cells with antibody to CD3 (anti-CD3) in the presence of the blocking antibodies to cytokines or 1-D-MT. The suppressive effect of pretreating cDCs with IL-27 was not blocked by the antibodies or 1-D-MT (Fig. 4a,b) , which suggested that neither IDO nor the cytokines IL-27, IL-10, IFN-β or TGF-β mediated the suppressive effects of cDCs pretreated with IL-27.
Expression of PD-L1 (CD274), the ligand for the T cell-inhibitory receptor PD-1, is reported to be upregulated following the treatment of mouse pDCs 20 or human monocyte-derived DCs 19 with IL-27. We did not detect substantial upregulation of PD-L1 expression after treating cDC with IL-27 ( Supplementary Fig. 6a ). Moreover, we also observed the suppressive effects of IL-27-treated cDCs on the activation of T cells when we used PD-L1-or IL-10-deficient cDCs (Supplementary Fig. 6b ). Together these data suggested that the suppressive effects of IL-27 on the antigen-presenting function of cDCs were independent of PD-L1 or IL-10.
CD39 has been linked to the suppressive activity of mouse and human T reg cells 25, 26 . Entpd1 (which encodes CD39) was significantly upregulated in DCs in response to treatment with IL-27 in vitro (P = 0.01; Supplementary Fig. 5c ). Hence, we investigated the role of CD39 in the effects of IL-27 on cDCs. Entpd1 deficiency abolished the suppressive effects of the pretreatment of DCs with IL-27 A r t i c l e s on the activation and polarization of T cells. Pretreatment of Entpd1-deficient cDCs with IL-27 did not significantly decrease the proliferative response and the production of IFN-γ and IL-17, and had no significant effect on IL-10 production and Foxp3 expression by 2D2 T cells (P = 0.2365; Fig. 4c and Supplementary Fig. 6b,c) . Thus, these data suggested that CD39 mediated the effects of IL-27 signaling in cDCs on T cell activation.
To further characterize the role of CD39 on the effects of IL-27 in DCs, we studied the regulation of CD39 expression by IL-27. Freshly isolated cDCs from DC(IL-27RA-KO) mice showed significantly lower expression of both Entpd1 mRNA and CD39 protein, reflected as a significant decrease in CD39 + DCs, than did their DC(WT) counterparts (Fig. 4d) . Thus, IL-27 controlled Entpd1 expression in cDCs in vitro and in vivo.
STAT1 and STAT3 mediate the response to IL-27 in T cells 17 . We detected significant phosphorylation of STAT3 in cDCs 5 min after treatment with IL-27 and a modest but significant increase in the phosphorylation of STAT1 (Fig. 4e,f) . Bioinformatics analysis identified a putative STAT1-binding element (IRF-1), two STAT3-binding elements (SRE-1 and SRE-2) and a common STAT1-STAT3-binding element upstream of the transcription start site in the Entpd1 promoter (Fig. 4g) . Chromatin-immunoprecipitation (ChIP) assays detected binding of STAT3 to SRE-1, SRE-2 and the STAT1-STAT3-binding element in the Entpd1 promoter in response to IL-27 (Fig. 4h) . Binding of STAT1 to the Entpd1 promoter, however, was unresponsive to IL-27 and was triggered by activation with ecLPS instead (Fig. 4i) .
To investigate the functional consequences of the interaction of STAT1 and STAT3 with the Entpd1 promoter, we did reporter assays. Cotransfection of HEK293 human embryonic kidney cells with a reporter construct containing the gene encoding firefly luciferase under the control of the Entpd1 promoter together with a construct encoding constitutively activated STAT1 or STAT3 led to significantly more in luciferase activity than did transfection of control cells with empty vector, but this effect was significantly stronger in response to constitutively activated STAT3 (Fig. 4j) . These data were in agreement with the reported effects of STAT3 on CD39 expression in T cells 27 and together suggested that IL-27 controlled CD39 expression in cDCs via STAT3.
CD39 controls activation of the NLRP3 inflammasome CD39 is an ectonucleotidase that catalyzes the degradation of extracellular ATP and ADP 28 . Extracellular ATP triggers activation of the NLRP3 inflammasome 29 , a process shown to control the differentiation of encephalitogenic T H 1 and T H 17 cells during EAE 30 . Given the requirement for CD39 expression in the effects of IL-27 signaling in cDCs on the activation and differentiation of T cells ( Fig. 4c and Supplementary Fig. 6 ), we investigated the effects of IL-27 on the extracellular concentration of ATP and activation of the NLRP3 inflammasome. Pretreatment with IL-27 and treatment with ecLPS led to a significant decrease the extracellular concentration of ATP detected after activation of wild-type cDCs with ecLPS (Fig. 5a) . However, pretreatment with IL-27 had no effect on the extracellular concentration of ATP measured in the supernatants of 
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IL-27RA-or CD39-deficient cDCs treated with ecLPS (Fig. 5a) . Moreover, deficiency in IL-27RA or CD39 in cDCs led to a significantly higher extracellular concentration of ATP detected after activation with LPS than that of their wild-type counterparts (Fig. 5a) .
To further investigate the mechanisms linked to the reduced amount of extracellular ATP detected in tissue culture supernatants of wild-type cDCs treated with IL-27, we added exogenous ATP (500 µM) to cDCs treated with LPS, vehicle or IL-27 and quantified the residual extracellular ATP in the supernatants after 2 h of incubation. We found significantly lower concentrations of extracellular ATP remaining in supernatants of wild-type cDCs treated with ecLPS and IL-27 than in those of wild-type cDCs treated with ecLPS (Fig. 5b) . However, IL-27 did not affect the amount of residual extracellular ATP in IL-27RA-or CD39-deficient cells (Fig. 5b) , which suggested that the lower abundance of ATP in supernatants of wildtype cDCs treated with IL-27 resulted from its increased catabolism by CD39. In agreement with that interpretation, treatment with IL-27 significantly increased nucleoside triphosphate diphosphohydrolase activity in wild-type cDCs but not in IL-27RA -or CD39-deficient cDCs (Fig. 5c,d) . Moreover, we detected less nucleoside triphosphate diphosphohydrolase activity (manifested as greater residual amounts of ATP) in IL-27RA-deficient DCs than in wild-type cDCs (Fig. 5c,d) , which suggested that the autocrine effects of IL-27 controlled the ability of cDCs to degrade extracellular ATP.
ATP activates the NLRP3 inflammasome in certain APCs such as macrophages 29 . Activation of the NLRP3 inflammasome results in the generation of active caspase 1, which leads to the maturation and release of IL-18 and IL-1β 31 . We found that pretreatment with IL-27 significantly suppressed activation of the NLRP3 inflammasome in wild-type cDCs activated with ecLPS, as shown by a lower abundance of activated caspase-1 and mature IL-1β (Fig. 5e) and the secretion of significantly lower amounts of IL-1β into the culture medium (Fig. 5f) . In accordance with our data on the extracellular concentrations of ATP, we did not detect the inhibitory effects of IL-27 on the activation of the NLRP3 inflammasome and the release of IL-1 β in ecLPS-treated IL-27RA-or CD39-deficient cDCs (Fig. 5e,f) .
Indeed, deficiency in IL-27RA or CD39 resulted in significantly more release of IL-1β than that of wild-type cDCs after treatment with ecLPS (Fig. 5f ). Together these data suggested that the upregulation of CD39 expression triggered by IL-27 limited extracellular ATP concentrations and, consequently, activation of the NLRP3 inflammasome in cDCs.
CD39 in DCs limits EAE development
To study the role of CD39 in DCs during EAE, we reconstituted CD11c-DTR→WT chimeras with CD39-deficient DC precursors to generate mice lacking Entpd1 expression in DCs (DC(CD39-KO) mice). We used DC(WT) mice as controls. We found significantly lower expression of CD39 protein in cDCs from DC(CD39-KO) mice than in cDCs from DC(WT) mice (Fig. 6a) , but did not obtain this result for other APC populations (Supplementary Fig. 6d ). We detected no difference between DC(WT) and DC(CD39-KO) mice in the frequency or absolute number of DCs (Supplementary Fig. 6e ). The induction of EAE led to an earlier onset of EAE in DC(CD39-KO) mice than in DC(WT) mice, and the EAE also reached significantly higher scores in the former (Fig. 6b) . The worsening of EAE in DC(CD39-KO) mice was correlated with an increased frequency of T H 1 and T H 17 cells in the CNS (Fig. 6c) . In agreement with the worsening of EAE associated with CD39 deficiency in DCs, DC(CD39-KO) splenic T cells had significantly enhanced proliferative recall response to MOG , and DC(CD39-KO) mice had a significantly greater frequency of CD4 + CD44 + CD40L hi splenic IFN-γ + and IL-17 + CD4 + T cells (Fig. 6d,e) . We observed no difference between DC(WT) and DC(CD39-KO) mice in the frequency of Foxp3 + T reg cells or IL-10 + CD4 + T cells (Fig. 6d,e) .
Analysis of cDCs isolated 21 d after the induction of EAE revealed significantly lower CD39 expression, concomitant with higher expression of mRNA encoding the proinflammatory cytokines IL-6, IL-12 and IL-23, in DC(CD39-KO) mice than in DC(WT) cells (Fig. 6f) . We found no significant difference between DC(WT) and DC(CD39-KO) Fig. 6f) . In vitro, cDCs from DC(CD39-KO) mice showed an increased ability to trigger the proliferation of naive 2D2 CD4 + T cells in the presence of MOG and induce the production of IL-17 and IFN-γ, at the expense of decreased secretion of IL-10 and TGF-β (Fig. 6g,h) . Thus, expression of CD39 in DCs limited the encephalitogenic T H 1 and T H 17 T cell response and the development of EAE.
Vaccination with IL-27-conditioned DCs suppresses EAE
The tolerogenic effects of IL-27 signaling in T cells and DCs support the proposal of its therapeutic potential in disorders mediated by the immune system. However, IL-27 is reported to act on T cells to boost cytotoxic CD8 + T cell responses 11 , which suggests that direct administration of IL-27 could potentially have detrimental side effects in immunologically mediated disorders. Vaccination with DCs induces immunity to tumors and pathogens 32 , but vaccination with tolerogenic DCs has been shown to induce antigen-specific tolerance 33 . Thus, given the tolerogenic effects of IL-27 signaling in DCs, and to avoid the potential pathogenic effects of IL-27 administration, we investigated the therapeutic effects of vaccination with IL-27-conditioned DCs on CNS autoimmunity. First we studied the effects of vaccination with IL-27-conditioned bone marrow-derived DCs on the model of relapsing-remitting EAE induced in SJL mice by immunization with a peptide of amino acids 139-151 of proteolipid protein (PLP(139-151) ). On day 20 after EAE induction, during the remission phase of the disease, we randomly allocated the mice into four groups and treated them as follows: group 1, saline only; group 2, DCs loaded with PLP(139-151); group 3, DCs treated with IL-27; group 4, DCs treated with IL-27 and loaded with PLP(139-151). An additional control group received DCs not loaded with peptide or pretreated with cytokine. We repeated the treatment three additional times, once every 4 d. DCs not loaded with peptide or pretreated with cytokine had no significant effect on disease development (P = 0.1487; Supplementary Fig. 7a) . However, the administration of IL-27-conditioned DCs loaded with PLP(139-151) led to a significant reduction in EAE and a significant reduction in the proliferative recall response (measured as the production of IFN-γ and IL-17) to PLP(139-151), concomitant with increased production of IL-10 and TGF-β, relative to results obtained for untreated mice (Fig. 7a-c) .
In this model, the chronic phase of EAE is characterized by spreading of the T cell response to the PLP epitope of amino acids 178-191 (PLP (178-191) ) 7 . Thus, we analyzed the recall response to PLP(178-191) in DC-vaccinated mice. We found that the administration of IL-27-treated DCs loaded with PLP(139-151) led to significant suppression of the proliferative response and production of IFN-γ and IL-17 triggered by PLP(178-191), concomitant with increased production of IL-10 and TGF-β, relative to the results obtained for untreated mice (Fig. 7d,e) . Thus, vaccination with IL-27-treated cDCs also seemed to reduce epitope spreading in this model of EAE. To further investigate the effects of IL-27-conditioned DCs on the immune response, we used myelin antigen arrays, which can detect epitope spreading in EAE and MS 34, 35 . The microarrays consisted of a collection of CNS-related autoantigens, including tissue lysates, recombinant proteins, and peptide libraries spanning the entire sequence of myelin proteins and lipids found in the central and peripheral nervous system 34 (Supplementary Table 1) . The therapeutic effect of vaccination with DCs on EAE in SJL mice was accompanied by a lower serum concentration of immunoglobulin G antibodies to 31 myelin antigens than that in untreated mice (Fig. 7f) .
We then studied the mechanisms involved in the suppression of EAE with IL-27-conditioned DCs; for this we used the C57BL/6 mouse model of EAE induced with MOG . We initiated the administration of IL-27-conditioned DCs 10 d after the induction of EAE. Vaccination with IL-27-conditioned wild-type DCs loaded with MOG(35-55) led to significantly diminished EAE relative to that of untreated mice (Supplementary Fig. 7b-d) . We observed similar suppression of EAE after the administration of MOG(35-55)-loaded, IL-27-conditioned DCs deficient in IL-10 or PD-L1 ( Supplementary  Fig. 7b-d) , which suggested that these molecules did not have a substantial role in regulating the encephalitogenic response by IL-27 signaling in DCs. Conversely, MOG(35-55)-loaded, IL-27-conditioned DCs deficient in IL-7RA or CD39 did not have a significant effect on EAE (P = 0.7979, P = 05708 and P = 0.5630, respectively; Supplementary Fig. 7b-d) . Together these data demonstrated that vaccination with IL-27-treated DCs controlled the encephalitogenic response and established relapsing-remitting EAE in a therapeutic paradigm in an CD39-dependent manner. DISCUSSION IL-27 limits tissue inflammation and autoimmunity in various scenarios 11 . Indeed, deficiency in the receptor for IL-27 is linked to the development of exacerbated inflammation in animal experimental models, and polymorphisms in IL-27 are associated with human inflammatory disorders 11 . The immunoregulatory actions of IL-27 are usually attributed to its direct effects on T cells, whereby it arrests the development of T H 17 cells and promotes the differentiation of Tr1 cells through mechanisms that involve the transcription factor AhR 26, 36 . In this work we identified an important role for IL-27 signaling in DCs in the control of the T cell response and CNS autoimmunity.
We found that CD39 was required for modulating the antigenpresenting function of cDCs by IL-27 in vitro and in vivo. However, IL-27 also upregulated the expression of additional immunoregulatory molecules, such as IL-27 itself, IFN-β, TGF-β and IDO. Although those molecules did not have a substantial role under the experimental conditions in which we tested them here, they might contribute to the suppressive effects of IL-27 on DCs in alternative scenarios.
IL-10, known to activate STAT3 signaling, has also been shown to induce a tolerogenic phenotype in DCs 37 . Conversely, STAT3 deficiency restricted to DCs results in the spontaneous development of inflammation 38 . Such data support the proposal of a tolerogenic role for STAT3 in DCs and suggest that other cytokines that activate STAT3 signaling might trigger CD39-dependent regulatory pathways similar to those triggered by IL-27. Moreover, microglia and tissue macrophages express CD39, and their function is also regulated by cytokines that activate STAT3 signaling 39, 40 . Thus, it is possible that the induction of CD39 expression constitutes a common immunoregulatory mechanism triggered by STAT3-activating cytokines in cells of the innate immune system. CD39 mediates the suppressive activity of mouse and human T reg cells, probably through the generation of adenosine 25, 26 . The mechanisms by which CD39 in APCs regulates adaptive immunity are less clear, but published data suggest that these effects involve controlling activation of the NLRP3 inflammasome. Extracellular ATP triggers A r t i c l e s such activation 28 . Initial support for the proposal of a role of ATPdependent NLRP3 activation in the control of T cell immunity was provided by the observation of augmented contact hypersensitivity in Entpd1-deficient mice 41 . Conversely, Nlrp3 deficiency results in decreased contact hypersensitivity 42 . Follow-up studies have determined that activation of the NLRP3 inflammasome in APCs controls T H 1, T H 2 and T H 17 responses 43, 44 . Indeed, activation of NLRP3 inflammasome is required for the differentiation of encephalitogenic T H 1 and T H 17 cells and the development of EAE 30 , probably as a result of its effects on the secretion of IL-1β and IL-18. In our studies, the induction of CD39 expression in DCs by IL-27 led to a significant reduction in the extracellular concentration of ATP, concomitant with a significant reduction in activation of the NLRP3 inflammasome and reduced differentiation of T H 1 and T H 17 cells. These data are compatible with a model in which, through the upregulation of CD39 expression, IL-27 limits ATP-dependent activation of the NLRP3 inflammasome in DCs and their ability to promote the differentiation of pathogenic T H 1 and T H 17 cells. It is possible, however, that in addition to its effects on CD39 expression, IL-27-triggered signaling directly interferes with the expression of components of the NLRP3 inflammasome and their activation in DCs.
The immunoregulatory properties of IL-27 support the proposal of its use for the treatment of human autoimmune diseases. However, IL-27 can boost cytotoxic CD8 + T-cell responses 11 , which suggests that the administration of IL-27 could potentially worsen disorders mediated by the immune system. Hence, to explore the therapeutic potential of IL-27 and avoid its potential deleterious side effects, we studied the effects of vaccination with IL-27-conditioned DCs. We found that vaccination with IL-27-conditioned DCs suppressed the encephalitogenic T H 1 and T H 17 response and halted established chronic EAE. Vaccination with DCs has been approved for the treatment of prostate cancer 45 ; thus, vaccination with IL-27-conditioned tolerogenic DCs might provide a new avenue for the treatment of autoimmune diseases. Alternatively, nanoparticles have been developed for the simultaneous activation of tolerogenic pathways and the delivery of antigens to APCs in vivo to induce antigen-specific tolerance 46 . Thus, it is conceivable that nanoparticles engineered to activate IL-27 signaling and deliver myelin antigens to DCs would induce tolerogenic DCs in vivo and arrest pathogenic T cell responses. That approach would exploit the immunoregulatory properties of IL-27 and overcome the limitations associated with the implementation of cell-based therapies in a clinical setting. In summary, we have reported here that IL-27 signaling in DCs limited the differentiation of pathogenic T H 1 and T H 17 cells and the development of CNS autoimmunity through a mechanism that was at least partially dependent on CD39. This immunoregulatory pathway might provide new therapeutic avenues for MS and other autoimmune disorders.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: microarray data, GSE49328. 
